Veysi Yilmaz

Veysi Yilmaz

Auto-generated profile, based on publicly available information

Veysi Yilmaz

Department of Dermatology, Marmara University School of Medicine, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
SYSehnaz Yuksel
Sehnaz Yuksel
TETulin Ergun
Tulin Ergun
OOOsman Cavit Ozdogan
Osman Cavit Ozdogan
YAYesim Ozen Alahdab
Yesim Ozen Alahdab
VYVeysi Yilmaz
Veysi Yilmaz
CDCoskun Ozer Demirtas
Coskun Ozer Demirtas
Background and Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis. Reliable non-invasive tools are needed to evaluate hepatic steatosis and to identify patients at risk for significant liver fibrosis. This study aimed to assess the discriminative performance of commonly used non-invasive scoring systems for identifying patients with vibration-controlled transient elastography (VCTE)-defined signifi-cant liver fibrosis and hepatic steatosis in patients with psoriasis. Materials and Methods: A total of 113 patients with psoriasis were prospectively enrolled. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were assessed using VCTE. Significant fibrosis (F2–F4) was defined as LSM ≥8 kPa, and significant steatosis (S2–S3) as CAP ≥259 dB/m. The discriminative performance of non-invasive fibrosis and steato-sis scores was evaluated using area under the receiver operating characteristic (AUROC) curves. Results: Of the 113 patients, 76 (67%) were diagnosed with MASLD following VCTE assess-ment. The body mass index, aspartate aminotransferase–alanine aminotransferase ratio, and diabetes (BARD) score (AUROC=0.692) showed the highest performance in identifying significant fibrosis, while FIB-4, aspartate aminotransferase to platelet ratio index, non-alco-holic fatty liver disease fibrosis score (NFS), and steatosis-associated fibrosis estimator (SAFE) demonstrated lower predictive accuracy. Among patients with MASLD, the SAFE score (AU-ROC=0.776), followed by the BARD score (AUROC=0.716), yielded the highest discriminative performance. The SAFE score showed the highest negative predictive value (95%) for ruling out significant fibrosis in MASLD patients. For detecting significant steatosis, the fatty liver index (FLI) score (AUROC=0.867) provided the highest performance, while hepatic steatosis index (HSI) (AUROC=0.813) and metabolic dysfunction–associated fatty liver disease screen-ing score (MAFLD-S) (AUROC=0.833) also demonstrated good discriminative ability. Conclusion: In patients with psoriasis, commonly used non-invasive fibrosis scores showed limited discrimination for VCTE-defined significant fibrosis, but they may have value as rule-out tools in low-prevalence settings. In contrast, FLI, HSI, and MAFLD-S showed good discrimination for VCTE-defined significant hepatic steatosis.